Paper - WANFANG MED ONLINE

You Position: Home > Paper

胰腺癌治疗靶点研究进展

( views:341, downloads:346 )

Author:: No author available

Journal Title:: Chinese Journal of Pancreatology

Issue:: 2

DOI:: 10.3760/cma.j.cn115667-20200416-00053

Key Word:: 胰腺导管腺癌;特异性治疗靶点;分子通路;抑癌基因;DNA修复因子;细胞外基质;微生物

Abstract：胰腺导管腺癌的发病机制与多条关键致癌信号通路包括Ras/MAPK、PI3K/AKT、PLCγ/PKC以及JAK/STATs等密切相关，而细胞外基质及微生物等对肿瘤发病的作用也逐渐被认识。越来越多新的潜在治疗靶点被发现，临床上对多种特异性治疗靶点抑制剂的应用取得了一定效果。化疗、靶向治疗、免疫治疗和基质靶向药物等联合治疗策略是胰腺导管腺癌未来的研究方向。

Reference

[1]Madelaine G,van Mackelenbergh,Charlotte I,Stroes,René,Spijker,etc.Clinical Trials Targeting the Stroma in Pancreatic Cancer: A Systematic Review and Meta-Analysis.[J].2019,11(5).
[2]Drilon, Alexander,Siena, Salvatore,Ou, Sai-Hong Ignatius,etc.Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)[J].2017,7(4).
[3]Kang, Xiaodiao,Lin, Zeng,Xu, Minhui,etc.Deciphering role of FGFR signalling pathway in pancreatic cancer[J].2019,52(3).
[4].Germline mutations in pancreatic cancer and potential new therapeutic options.[J].2017,(Spec).
[5]Karavasilis, Vasilios,Samantas, Epaminontas,Koliou, Georgia-Angeliki,etc.Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study[J].2018,13(6).
[6]Drilon, A.,Laetsch, T. W.,Kummar, S.,etc.Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children[J].2018,378(8).
[7]Edgardo D'Angelo.Mechanisms controlling inspiration studied be electrical vagal stimulations in rabbits[J].1979,38(2).
[8]Fetscher, Sebastian,Schlesner, Matthias,Glimm, Hanno,etc.NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer[J].2018,8(9).
[9]Propper, David,Venugopal, Balaji,Jodrell, Duncan,etc.A phase I trial of the gamma-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma[J].2018,118(6).
[10]Blaszkowsky LS,Abrams T,Hezel AF,etc.Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.[J].2009,27(2).
[11]Kishore, Polireddy,Qi, Chen.Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment.[J].2016,(11).
[12]Golan, Talia,Hammel, Pascal,Reni, Michele,etc.Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer[J].2019,381(4).
[13]Fan, Xiaozhou,Alekseyenko, Alexander V.,Wu, Jing,etc.Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study[J].2018,67(1).
[14]Shravanti,Macherla,Shachar,Laks,Abdul Rafeh,Naqash,etc.Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer.[J].2018,19(11).
[15]Loh,E.,Bray,S.L.,Kocs,D.M.,etc.A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer[J].2012,23(11).
[16]Avnish,Kapoor,Wantong,Yao,Haoqiang,Ying,etc.Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer.[J].2019,179(5).
[17]Bray Freddie,Ferlay Jacques,Soerjomataram Isabelle,etc.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].2018,68(6).
[18]Lai, Eleonora,Puzzoni, Marco,Ziranu, Pina,etc.New therapeutic targets in pancreatic cancer[J].2019,81.
[19]Buscail, Louis,Bournet, Barbara,Cordelier, Pierre.Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer[J].2020,17(3).
[20]T Golan,Z S Kanji,R Epelbaum,etc.Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.[J].2014,111(6).
[21]Hidalgo, Manuel,Cascinu, Stefano,Kleeff, Jorg,etc.Addressing the challenges of pancreatic cancer: Future directions for improving outcomes[J].2015,15(1).
[22]Kozloff, Mark,Fuchs, Martin,Gueorguieva, Ivelina,etc.Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer[J].2018,119(10).
[23]Sahin, Ibrahim H.,Iacobuzio-Donahue, Christine A.,O'Reilly, Eileen M..Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy[J].2016,20(3).
[24]Constanta Timcheva,N C Tebbutt,Gy?rgy Bodoky,etc.A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.[J].2012,30(3).
[25]Eric A Collisson,Peter Bailey,David K Chang,etc.Molecular subtypes of pancreatic cancer.[J].2019,16(4).
[26]Ebrahimi, Safieh,Hosseini, Mina,Shahidsales, Soodabeh,etc.Targeting the Akt/PI3K Signaling Pathway as a Potential Therapeutic Strategy for the Treatment of Pancreatic Cancer[J].2017,24(13).
[27]Le, Dung T.,Durham, Jennifer N.,Smith, Kellie N.,etc.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J].2017,357(Jul.28 TN.6349).
[28]Geller, Leore T.,Barzily-Rokni, Michal,Danino, Tal,etc.Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine[J].2017,357(Sep.15 TN.6356).